69) inical levels of disruptive behavior post-treatment. |
70) maintained from 3 months to 2 years post-treatment. |
71) 18F]FLT uptake in vivo following systemic treatment. |
72) d in the context of arterial hypertension treatment. |
73) , and behavior modification as first-line treatment. |
74) ght the clinical benefits of psychosocial treatment. |
75) to more realistically model in vitro drug treatment. |
76) sectomy, and had never sought infertility treatment. |
77) is rapidly emerging as a promising cancer treatment. |
78) the development of further approaches to treatment. |
79) work-related plans after prostate cancer treatment. |
80) e now the standard of care and first-line treatment. |
81) orescent Mtb cells within 10 min of probe treatment. |
82) n primary human hepatocytes after alcohol treatment. |
83) adual than expected after prostate cancer treatment. |
84) hat function as alternatives to inpatient treatment. |
85) hese conditions and inform evaluations of treatment. |
86) ne uptake an attractive target for cancer treatment. |
87) the major limiting factors for long-term treatment. |
88) ate a potential benefit of corticosteroid treatment. |
89) r, the impact of cancer does not end with treatment. |
90) players in tuberculosis (TB) outcomes and treatment. |
91) uided immature follicle aspiration (IMFA) treatment. |
92) n for prompt diagnosis and individualized treatment. |
93) ntent of WPI reduced with the cold plasma treatment. |
94) ge III NSCLC treated with radiation-based treatment. |
95) ild and adolescent mental health care and treatment. |
96) ltered histamine metabolism with nicotine treatment. |
97) rs and understanding of interventions and treatment. |
98) may be negatively impacted by cancer and treatment. |
99) ce of PEAK1-expressing MSCs and lapatinib treatment. |
100) and prognosis of illness and response to treatment. |
101) ry, which is considered the gold standard treatment. |
|